Utilizing Constrained Bicyclic Peptides for In Vitro Diagnostics
ACS Nano · 2026
DOI: 10.1021/acsnano.5c19041 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von André Shamsabadi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Materials, Department of Bioengineering and Institute of Biomedical Engineering, Imperial College London, London SW7 2AZ, U.K. Hauptthemen laut MEDLINE: SARS-CoV-2, Peptides, Cyclic, COVID-19, Nucleocapsid Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council, Royal Academy of Engineering, Innovate UK.
Abstract (Originalsprache)
High Resolution Image Download MS PowerPoint Slide Constrained bicyclic peptides ( Bicycle molecules ) with high affinity for biological targets have emerged as potentially powerful therapeutic agents, particularly for the in vivo targeting of cancer receptors. However, their antibody-mimetic properties have yet to be explored for use in diagnostic immunoassays. These synthetically derived compounds serve as biorecognition scaffolds that allow for facile site-selective modification and large-scale production. A phage display screen against various constructs of the SARS-CoV-2 nucleocapsid (N) protein identified several Bicycle molecules with binding affinities ranging from the micromolar to the low nanomolar range. These Bicycle molecules were validated in the development of enzyme- and nanozyme-linked immunosorbent assays, as well as enzymatic and colorimetric nanoparticle-based lateral flow immunoassays (LFIA) for the detection of ultralow concentrations of the SARS-CoV-2 N protein. We envision that these moieties enable robust, cost-effective, and large-scale development of ultrasensitive biosensors for a diverse range of biomarkers by leveraging their high binding affinity, minimalistic scaffold, and synthetic accessibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Materials, Department of Bioengineering and Institute of Biomedical Engineering, Imperial College London, London SW7 2AZ, U.K.
- Bicycle Therapeutics, Portway Building, Granta Park, Cambridge CB21 6GS, U.K.
- Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA, U.K.
ORCID-Profile: Christy J Sadler, Katerine Van Rietschoten, Liuhong Chen, Gustavo Arruda Bezerra, Paul Brear, Marko Hyvönen, Michael J Skynner, Molly M Stevens
Förderung
- Engineering and Physical Sciences Research Council
- Royal Academy of Engineering
- Innovate UK
- Rosetrees Trust
- Cancer Research UK
Zitieren
APA
Shamsabadi, A., Creamer, A., Sadler, C. J., Abdelwahed, A., Gaynor, K. U., Demydchuk, Y., Ivanova-Berndt, G., Van Rietschoten, K., Beswick, P., Chen, L., Arruda Bezerra, G., Lulla, A., Brear, P., Hyvönen, M., Skynner, M. J., & Stevens, M. M. (2026). Utilizing Constrained Bicyclic Peptides for In Vitro Diagnostics. ACS Nano. https://doi.org/10.1021/acsnano.5c19041
Vancouver
Shamsabadi A, Creamer A, Sadler CJ, Abdelwahed A, Gaynor KU, Demydchuk Y, et al. Utilizing Constrained Bicyclic Peptides for In Vitro Diagnostics. ACS Nano. 2026. doi:10.1021/acsnano.5c19041
BibTeX
@article{Shamsabadi2026,
author = {Shamsabadi, André and Creamer, Adam and Sadler, Christy J and Abdelwahed, Aida and Gaynor, Katherine U and Demydchuk, Yuliya and Ivanova-Berndt, Gabriela and Van Rietschoten, Katerine and Beswick, Paul and Chen, Liuhong and Arruda Bezerra, Gustavo and Lulla, Aleksei and Brear, Paul and Hyvönen, Marko and Skynner, Michael J and Stevens, Molly M},
title = {Utilizing Constrained Bicyclic Peptides for In Vitro Diagnostics},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.5c19041}
}
EUVIMED